GlassScriptPhysician profile
Charles A Craton
NPI 1568435501
$13,363.53
in general payments reported to CMS, 2019-2025
46 companies · $1,527 in 2025
The $1,527 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,041 · 2020: $1,700 · 2021: $1,717 · 2022: $1,760 · 2023: $2,521 · 2024: $2,097 · 2025: $1,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,145.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,085.21 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,899.11 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,413.29 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $994.79 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $687.54 | 2019-2022 | |
| Abbvie INC. | $686.81 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $610.91 | 2019-2025 | Jardiance, Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $603.24 | 2021-2025 | |
| Abbott Laboratories | $468.33 | 2019-2025 | Freestyle Libre 3 |
| Pfizer INC. | $460.17 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $405.46 | 2019-2024 | |
| Glaxosmithkline, LLC. | $385.09 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $346.24 | 2019-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $276.35 | 2019-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $250.09 | 2019-2024 | Verquvo, Belsomra, Capvaxive |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Craton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.